Sponsor decision to deprioritize the dengue program

The Phase 2 study will be conducted in adult patients with confirmed Dengue infection and will investigate safety, PK, and pharmacodynamics (PD) in this population. The study will be conducted in several dosing cohorts to enable dose selection for subsequent trials

Key Inclusion Criteria:

• 18-55 years of age at time of screening
• Fever ≥38°C (or feeling feverish) with onset during the previous 48 hours
• Live/work in or recent travel to dengue endemic area
• Positive test confirming Dengue (DENV) on a NS1 antigen test or reverse transcription-polymerase chain reaction (RT-PCR) assay
• Negative rapid diagnostic test result for Coronavirus (SARS-CoV-2) and Influenza A and B

Key Exclusion Criteria:

• Pregnant, plans to become pregnant within 90 days of screening, or breast feeding.
• Has previously received any investigational or approved vaccine for dengue
• Previous history of HIV, chronic hepatitis B infection, or current hepatitis C infection (from medical history)
• Use of any antiviral drug within 30 days or within 5 half-lives of the active drug or metabolite (for long-acting antivirals)
• Current use of anticoagulant or antiplatelet drugs or documented medical history of bleeding disorders
• Current use of medications for treatment of inflammatory bowel disease or documented medical history of chronic gastrointestinal disease including inflammatory bowel disease
• Immunocompromised due to use of immunosuppressive drugs including systemic corticosteroids (inhaled or topical corticosteroids are allowed) or any current disease or condition
• Evidence of severe dengue disease
• Confirmed or suspected Coronavirus (SARS-CoV-2) infection or contact with patients with confirmed SARS-CoV2 infection within 7 days prior to screening
• Other clinically significant medical conditions or laboratory abnormalities, as described in the protocol.

Eligible subjects will be randomized to receive either AT-752 or matching placebo orally 3 times a day (TID) for 5 days in Cohort 1 of the study.

Subsequent cohorts will receive AT-752/placebo either twice a day (BID) or TID

Principal Investigator may publish or present results pertaining to the PI's activities after the first publication of the multicentre clinical trial results. Publications must be submitted for review by Sponsor before submission. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.